Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

Hydroxypinacolone retinoate is a potent anti-aging ingredient for skin that is more effective and less irritating than other forms of retinoids.

RSPO1 could help create new diabetes treatments by increasing pancreatic β cells.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.

LGD1069 effectively prevents breast tumors in mice without toxicity.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Ritlecitinib is effective long-term for treating alopecia areata in teens.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.

Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.